Develops novel immuno-oncology therapies utilizing its proprietary TriKE technology to engage and activate the immune system against cancer cells.
GT Biopharma, Inc. is a clinical stage biopharmaceutical firm specializing in immuno-oncology products leveraging its proprietary Tri-specific Killer Engager (TriKE) fusion protein technology platform. At the forefront of its pipeline is GTB-3550, an innovative single-chain tri-specific recombinant fusion protein currently undergoing Phase I/II clinical trials. This product is designed for treating challenging conditions such as myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia, advanced systemic mastocytosis, and CD33+ malignancies.
Additionally, GT Biopharma, Inc. is advancing GTB-3650 through preclinical studies, focusing on targeting CD33 in myeloid leukemias. Another promising candidate, GTB-5550, is also in preclinical development, aimed at addressing B7-H3 positive solid tumors. The company has forged strategic collaborations, including a co-development partnership with Altor BioScience Corporation to advance a 161533 TriKE fusion protein for cancer therapies. Moreover, GT Biopharma holds a license agreement with the Regents of the University of Minnesota, facilitating the development and commercialization of cancer treatments utilizing TriKE technology.
Formerly known as OXIS International, Inc., GT Biopharma, Inc. underwent a name change in July 2017. Established in 1965 and headquartered in Brisbane, California, the company continues to pioneer advancements in immuno-oncology, aiming to revolutionize cancer treatment paradigms through its innovative therapeutic approaches.